These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Use of Direct Oral Anticoagulants for Treating Venous Thromboembolism in Patients With Cancer. Soff GA J Natl Compr Canc Netw; 2018 May; 16(5S):670-673. PubMed ID: 29784753 [TBL] [Abstract][Full Text] [Related]
4. Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC). Rafii H; Frère C; Benzidia I; Crichi B; Andre T; Assenat E; Bournet B; Carpentier A; Connault J; Doucet L; Durant C; Emmerich J; Gris JC; Hij A; Le Hello C; Madelaine I; Messas E; Ndour A; Villiers S; Marjanovic Z; Ait Abdallah N; Yannoutsos A; Farge D J Med Vasc; 2020 Feb; 45(1):28-40. PubMed ID: 32057323 [TBL] [Abstract][Full Text] [Related]
5. Management of cancer-associated venous thromboembolism - a case-based practical approach. Voigtlaender M; Langer F Vasa; 2018 Feb; 47(2):77-89. PubMed ID: 29325495 [TBL] [Abstract][Full Text] [Related]
6. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. Khorana AA; Streiff MB; Farge D; Mandala M; Debourdeau P; Cajfinger F; Marty M; Falanga A; Lyman GH J Clin Oncol; 2009 Oct; 27(29):4919-26. PubMed ID: 19720907 [TBL] [Abstract][Full Text] [Related]
7. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Schulman S; Goldhaber SZ; Kearon C; Kakkar AK; Schellong S; Eriksson H; Hantel S; Feuring M; Kreuzer J Thromb Haemost; 2015 Jul; 114(1):150-7. PubMed ID: 25739680 [TBL] [Abstract][Full Text] [Related]
8. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. Kuderer NM; Ortel TL; Francis CW J Clin Oncol; 2009 Oct; 27(29):4902-11. PubMed ID: 19738120 [TBL] [Abstract][Full Text] [Related]
9. Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Streiff MB; Holmstrom B; Angelini D; Ashrani A; Elshoury A; Fanikos J; Fertrin KY; Fogerty AE; Gao S; Goldhaber SZ; Gundabolu K; Ibrahim I; Kraut E; Leavitt AD; Lee A; Lee JT; Lim M; Mann J; Martin K; McMahon B; Moriarty J; Morton C; Ortel TL; Paschal R; Schaefer J; Shattil S; Siddiqi T; Sudheendra D; Williams E; Hollinger L; Nguyen MQ J Natl Compr Canc Netw; 2021 Oct; 19(10):1181-1201. PubMed ID: 34666313 [TBL] [Abstract][Full Text] [Related]
10. Prophylaxis and treatment of venous thromboembolism in cancer patients: a review. Ansell JE Am J Clin Oncol; 2009 Aug; 32(4 Suppl):S8-S12. PubMed ID: 19654482 [TBL] [Abstract][Full Text] [Related]
11. Anticoagulation therapy for prevention and treatment of venous thromboembolic events in cancer patients: a review of current guidelines. Petersen LJ Cancer Treat Rev; 2009 Dec; 35(8):754-64. PubMed ID: 19762155 [TBL] [Abstract][Full Text] [Related]
13. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism. Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949 [TBL] [Abstract][Full Text] [Related]
14. Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach. Black SA; Cohen AT Thromb Haemost; 2015 Oct; 114(4):660-9. PubMed ID: 26084864 [TBL] [Abstract][Full Text] [Related]
15. Assessing the risk of recurrent venous thromboembolism--a practical approach. Fahrni J; Husmann M; Gretener SB; Keo HH Vasc Health Risk Manag; 2015; 11():451-9. PubMed ID: 26316770 [TBL] [Abstract][Full Text] [Related]
16. The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: strategies for improving VTE prophylaxis in hospitalized cancer patients. Khorana AA Oncologist; 2007 Nov; 12(11):1361-70. PubMed ID: 18055857 [TBL] [Abstract][Full Text] [Related]
18. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial. McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207 [TBL] [Abstract][Full Text] [Related]
19. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens. Trujillo-Santos J; Di Micco P; Dentali F; Douketis J; Díaz-Peromingo JA; Núñez MJ; Cañas I; Mastroiacovo D; Saraiva de Sousa M; Monreal M; Thromb Haemost; 2017 Jan; 117(2):382-389. PubMed ID: 27786333 [TBL] [Abstract][Full Text] [Related]
20. Deep-vein thrombosis in malignancy: how long should patients be treated, and with what? Merli GJ Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S27-34. PubMed ID: 19530157 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]